Trial Profile
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 228 in Subjects With Selected Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2022
Price :
$35
*
At a glance
- Drugs AMG 228 (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Amgen
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 12 Jan 2017 Status changed from active, no longer recruiting to discontinued.
- 09 Nov 2016 Status changed from recruiting to active, no longer recruiting.